Apotex: Amgen's Arguments Miss The Mark, Hypocritical
This article was originally published in Scrip
Executive Summary
California-based Amgen Inc.'s arguments opposing a motion by Apotex Inc. to expedite its appeal of a Florida district court's decision to impose a preliminary injunction (PI), which would block the Canadian firm from marketing its yet-to-be approved pegfilgrastim biosimilar in the US until six months after licensure, miss the mark and are hypocritical, the latter company asserted in court documents on Dec. 22.